TNAP inhibition effectively reduces pathological valve calcification by suppressing interconnected oxidative, inflammatory, fibrotic, and osteogenic pathways, positioning it as a promising and safe therapeutic approach for CAVD.
TNAP expression was highly elevated in calcific aortic valves in a vitamin D3-induced mouse model of CAVD.
Treatment with novel TNAP inhibitors significantly lowered TNAP levels and attenuated valvular calcification in the mouse model.
TNAP inhibitor treatment suppressed lipid peroxidation and restored antioxidant capacity in calcific aortic valves.
TNAP inhibitor treatment markedly decreased pro-inflammatory cytokine levels in diseased aortic valves.
TNAP inhibitor treatment reduced apoptotic markers in calcific aortic valve tissue.
TNAP inhibitor treatment diminished fibrotic and osteogenic remodeling in aortic valve tissue while maintaining normal bone homeostasis.
TNAP drives phosphate-mediated mineralization and is a mechanistic driver of CAVD progression.
This research suggests that blocking an enzyme called tissue non-specific alkaline phosphatase (TNAP) may be an effective way to treat calcific aortic valve disease (CAVD), a condition where the heart's aortic valve becomes stiff and calcified over time. The researchers used a mouse model that mimics the human form of the disease and tested new drug compounds designed to inhibit TNAP's activity. They found that when TNAP was blocked, calcium deposits in the valve were significantly reduced, and the valve tissue showed lower levels of harmful inflammation, oxidative stress (a form of cellular damage), cell death, and scarring. A particularly notable finding was that the TNAP inhibitors not only reduced harmful calcification in the heart valve but also restored the tissue's natural antioxidant defenses, as measured by multiple biological markers. Importantly, the treatment appeared to be safe in the sense that normal bone health was preserved in the treated mice, which is a significant concern when targeting an enzyme involved in mineralization processes throughout the body. This research suggests that TNAP inhibition could represent a new medical treatment strategy for CAVD, a disease that currently has no approved drug therapies and often requires surgical valve replacement. By addressing multiple interconnected disease processes simultaneously — oxidative stress, inflammation, scarring, and abnormal calcification — TNAP inhibitors may offer a more comprehensive approach to slowing or halting the progression of this condition.
Kwon H, Kim H, Kwon M, Jo S, Hwang G, Ku S, et al.. (2026). Inhibiting TNAP Attenuates the Aortic Valve Calcification and Reduces Oxidative Stress.. Cells. https://doi.org/10.3390/cells15171543